Literature DB >> 15316197

Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status.

Biagio R Di Iorio1, Davide Stellato, Natale G De Santo, Massimo Cirillo.   

Abstract

BACKGROUND: Female gender is associated with high erythropoietin (EPO) resistance in end-stage renal disease. The aim of our study was to investigate the roles of age and menstrual status in this relationship.
METHODS: Cross-sectional analysis of registry data for 3,224 hemodialysis adults treated with EPO. Data collection included gender, age, weight, height, dialytic age, hemoglobin, EPO dose, and, for women with ages 25-44 only, also information on menstrual status and iron homeostasis. EPO resistance index (ERI) was calculated as EPO dose per kilogram BW/hemoglobin.
RESULTS: Men and women had not significantly different hemoglobin and significantly different EPO dose per kilogram weight (women vs. men, +18.2%, p < 0.001). Thus, ERI was higher in women than in men (+19.5%, p < 0.001). The gender-associated difference in ERI linearly decreased along age groups: +30.9% for ages 25-44, +23.2% for ages 45-64, and +14.2% for ages 65-84 (p < 0.05 for interaction between age and gender-associated difference in ERI). Within the subgroup of women with ages 25-44, women with menses in comparison to women without had 44.6% higher ERI (p < 0.01) due to combination of lower hemoglobin (p < 0.05) with higher EPO dose (p < 0.001). Women with menses had also lower serum iron, transferrin saturation, and serum ferritin (p < 0.001).
CONCLUSION: The gender-associated difference in ERI is lower with increasing patients' age. The large difference between young men and women is due to women with menses who have iron deficiency more frequently than women without periods.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316197     DOI: 10.1159/000080234

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  7 in total

1.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

2.  Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.

Authors:  Oluwatoyin Fatai Bamgbola; Fredrick J Kaskel; Maria Coco
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

3.  Dialyzing women and men: does it matter? An observational study.

Authors:  Ayse Serra Artan; Fatih Kircelli; Ercan Ok; Murvet Yilmaz; Gulay Asci; Cengiz Dogan; Ozgur Oto; Kutay Gunestepe; Ali Basci; Mehmet Sukru Sever
Journal:  Clin Kidney J       Date:  2016-04-07

4.  Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.

Authors:  Alicja Ryta; Michal Chmielewski; Alicja Debska-Slizien; Piotr Jagodzinski; Malgorzata Sikorska-Wisniewska; Monika Lichodziejewska-Niemierko
Journal:  Int Urol Nephrol       Date:  2017-01-05       Impact factor: 2.370

5.  Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.

Authors:  Iain A Gillespie; Iain C Macdougall; Sharon Richards; Vincent Jones; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-02-17       Impact factor: 2.890

6.  Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Authors:  Sunil V Badve; Lei Zhang; Jeff S Coombes; Elaine M Pascoe; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Can J Kidney Health Dis       Date:  2015-08-18

7.  ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.

Authors:  Takahiro Kuragano; Kenichiro Kitamura; Osamu Matsumura; Akihiko Matsuda; Taiga Hara; Hideyasu Kiyomoto; Toshiaki Murata; Shouichi Fujimoto; Hiroki Hase; Nobuhiko Joki; Atushi Fukatsu; Toru Inoue; Yukihiro Itakura; Takeshi Nakanishi
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.